iRadimed Corp (IRMD) (Q2 2026) Earnings Call Highlights: Strong Demand for New 3,870 Pump ...
iRadimed Q2 Earnings Call Highlights
IRADIMED (NASDAQ:IRMD) Beats Q2 EPS, Reaffirms Full-Year Guidance
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est
iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est
CORRECTION: iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $91.300M Est
iRadimed Sees Q3 GAAP EPS $0.49-$0.54 vs $0.49 Est
Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
Assessing IRADIMED (IRMD) Valuation After Strong Multi Year Returns And A Premium P/E Multiple
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report
Iradimed’s CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Reaffirmed Outlook And Dividend: What Does IRMD’s Confidence Signal About Its MRI Pump Moat?
Here's What We Like About IRADIMED's (NASDAQ:IRMD) Upcoming Dividend
A Look At IRADIMED (IRMD) Valuation As Long Term Returns Contrast With Recent Share Price Weakness
IRadimed Corporation Q1 2026 Earnings Call Summary
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.